Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MedTech

Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's…

The Economic Times

STERIS Q4 Earnings Call Highlights

STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027. Senior Vice P

MarketBeat

Canvas Hacked Update: Who Are the Hackers and How Long Will the LMS Be Down?

A cyberattack on the Canvas LMS disrupted access to coursework and exams at major US universities during finals week, with a ransom note from ShinyHunters.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

From drought to demand: Biotech IPOs roar back with Kailera and Alamar

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks up most venture dollars.

Fortune

Stryker Cyberattack Sparks Health Sector Alert as Iran-Linked Hackers Target Medtech Firm Serving 150M Patients

Learn about the impact on global healthcare operations and the urgent measures being taken to protect patient care and MedTech security

International Business Times UK

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

MarketBeat

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why Requirements Management Is Critical in Regulated Device Development

In the development of regulated medical devices, adherence to stringent regulatory requirements is not optional but a foundational necessity. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others around the world enforce strict guidelines to ensure the safety, efficacy, and reliability…

inkl

Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

MarketBeat

AngioDynamics Eyes Growth Despite Tariffs

AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Benzinga

What's Fueling The Momentum In AngioDynamics Stock?

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.

Benzinga

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Barchart

3 Dividend Stocks to Hold Through Market Volatility This Fall

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

MarketBeat

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

JNJ Stock Surge Signals Confidence in New Growth Path

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

Barchart

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Benzinga

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Benzinga

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

MarketBeat

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

Barchart

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

MarketBeat

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

Barchart

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Barchart

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.